As the latest molecule in the mucoactive drug class Erdosteine has recently received Orphan-Drug Designation from the FDA. Erdosteine was developed by Edmond Pharma and this productive drug is already marketed in 40 countries around the world for the treatment of both chronic obstructive pulmonary disease (COPD) and chronic bronchitis. There are currently no medications[…]
Erdosteine Attains Orphan-Drug Status from the FDA
Drug Research & Development API, FDA Orphan Drug Status Tags: chronic bronchitisCOPD Jun 17, 2014
Olodaterol Offers Encouraging Results for Patients with COPD
Anti-Asthma / COPD Tags: chronic bronchitisCOPD Sep 16, 2013
In late January 2013, Olodaterol CAS# 868049-49-4 was the focus of an FDA committee reviewing data for the drug’s approval as a once-daily maintenance bronchodilator to treat chronic obstructive pulmonary disease (COPD), as well as chronic bronchitis and emphysema. The FDA Pulmonary-Allergy Drugs Advisory Committee recommended that the clinical data from the Boehringer Ingelheim Phase III studies[…]
The Demand for Roflumilast Set to Rise for COPD Patients
Blood Product, Patent Expiration 2015 Tags: chronic bronchitisCOPD Sep 12, 2012
Roflumilast, CAS number 162401-32-3, is also known by the brand name Daliresp. The patent for Daliresp, which is marketed by Forest Pharmaceuticals, is due to expire on Jan 27, 2015. Patients with severe chronic obstructive pulmonary disease, or COPD, find that treatment with roflumilast is efficacious at reducing flare ups of their condition, especially those[…]
